NCT06183216View on ClinicalTrials.gov

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

February 15, 2025

Study Completion Date

July 21, 2025

Conditions
Pneumococcal Infectious Disease
Interventions
BIOLOGICAL

Sinovac PCV13

0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

BIOLOGICAL

PREVNAR 13

0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

Trial Locations (1)

671600

Binchuan County Center for Diseases Control and Prevention, Dali

All Listed Sponsors
lead

Sinovac Research and Development Co., Ltd.

INDUSTRY

NCT06183216 - A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine | Biotech Hunter | Biotech Hunter